Chronic Kidney DiseasePhase 3OPPORTUNITYNCT00503698
The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis
A Phase 3 study testing somatropin in people with Chronic Kidney Disease and End-Stage Renal Disease, run by Novo Nordisk A/S at 381 sites in 21 countries.
Trial summary
This trial is conducted in Africa, Asia, Europe, North and South America and Oceania. The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health related quality of life in adult patients on chronic haemodialysis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Kidney Disease, End-Stage Renal Disease
- What is being tested?
- somatropin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 712 participants
- Where
- 381 sitesin 21 countries
- Study dates
- Jul 2007to Dec 2008
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Serum albumin as specified in protocol
- Malnourished (based on serum albumin value below 40 g/L, assessed centrally)
- Stable (for 3 months or more) and adequate haemodialysis treatment three months prior to enrolment as defined by Kt/V of more than 1.2
Who cannot join
- Active malignant disease
- Critical illness requiring treatment in an intensive care unit (ICU)
- Uncontrolled treated/untreated hypertension
- Patients on chronic (more than 3 months) treatment with steroids in doses of more than 10 mg/day prednisolone (or equivalent)
- Patients treated with immunosuppressive agents
- Known Growth Hormone Deficiency
- Patients suffering from any clinically significant disease history in the opinion of the investigator
- Severe illness as defined in the protocol (as judged by the investigator)
Trial locations and contacts
381 sites in 21 countries.
381 sites in 21 countries
United States209 sites
Novo Nordisk Investigational Site
Albuquerque, New Mexico, 87106
Novo Nordisk Investigational Site
Alexander City, Alabama, 35010
Novo Nordisk Investigational Site
Alexandria, Virginia, 22304
Novo Nordisk Investigational Site
Allentown, Pennsylvania, 18103
Novo Nordisk Investigational Site
Arlington, Texas, 76105
Novo Nordisk Investigational Site
Atlanta, Georgia, 30329
Novo Nordisk Investigational Site
Atlanta, Georgia, 30331
Novo Nordisk Investigational Site
Atlantis, Florida, 33462
Novo Nordisk Investigational Site
Augusta, Georgia, 30901
Novo Nordisk Investigational Site
Augusta, Georgia, 30912-3260
Novo Nordisk Investigational Site
Baton Rouge, Louisiana, 70809
Novo Nordisk Investigational Site
Bend, Oregon, 97701
Novo Nordisk Investigational Site
Bethesda, Maryland, 20814
Novo Nordisk Investigational Site
Beverly Hills, California, 90211
Novo Nordisk Investigational Site
Billings, Montana, 59101
Novo Nordisk Investigational Site
Birmingham, Alabama, 35211
Novo Nordisk Investigational Site
Bluefield, West Virginia, 24701
Novo Nordisk Investigational Site
Boise, Idaho, 83706
Novo Nordisk Investigational Site
Boston, Massachusetts, 02215
Novo Nordisk Investigational Site
Brandon, Florida, 33511
Novo Nordisk Investigational Site
Brockton, Massachusetts, 02301
Novo Nordisk Investigational Site
Brooklyn, New York, 11212
Novo Nordisk Investigational Site
Brooklyn, New York, 11226
Novo Nordisk Investigational Site
Buffalo, New York, 14086
Novo Nordisk Investigational Site
Buffalo, New York, 14209
Novo Nordisk Investigational Site
Burlington, Vermont, 05401
Novo Nordisk Investigational Site
Charleston, South Carolina, 29425
Novo Nordisk Investigational Site
Charlottesville, Virginia, 22902
Novo Nordisk Investigational Site
Chesapeake, Virginia, 23320
Novo Nordisk Investigational Site
Chula Vista, California, 91910
Novo Nordisk Investigational Site
City of Saint Peters, Missouri, 63376
Novo Nordisk Investigational Site
Clarksville, Tennessee, 37043
Novo Nordisk Investigational Site
Cleveland, Ohio, 44109
Novo Nordisk Investigational Site
Colorado Springs, Colorado, 80909
Novo Nordisk Investigational Site
Columbia, South Carolina, 29209
Novo Nordisk Investigational Site
Columbus, Mississippi, 39705
Novo Nordisk Investigational Site
Columbus, Ohio, 43210
Novo Nordisk Investigational Site
Cooperstown, New York, 13326
Novo Nordisk Investigational Site
Coral Springs, Florida, 33071
Novo Nordisk Investigational Site
Corpus Christi, Texas, 78404
Novo Nordisk Investigational Site
Corpus Christi, Texas, 78411
Novo Nordisk Investigational Site
Covina, California, 91723
Novo Nordisk Investigational Site
Crestwood, Illinois, 60445
Novo Nordisk Investigational Site
Dallas, Texas, 75235
Novo Nordisk Investigational Site
Dallas, Texas, 78216
Novo Nordisk Investigational Site
Dayton, Ohio, 45428
Novo Nordisk Investigational Site
Dearborn, Michigan, 48126
Novo Nordisk Investigational Site
Denver, Colorado, 80220
Novo Nordisk Investigational Site
Des Moines, Iowa, 50309
Novo Nordisk Investigational Site
Detroit, Michigan, 48202
Novo Nordisk Investigational Site
Detroit, Michigan, 48236
Novo Nordisk Investigational Site
Durham, North Carolina, 27710
Novo Nordisk Investigational Site
Dyersburg, Tennessee, 38024
Novo Nordisk Investigational Site
Easton, Maryland, 21601
Novo Nordisk Investigational Site
Eatontown, New Jersey, 07724
Novo Nordisk Investigational Site
El Dorado, Arkansas, 71730
Novo Nordisk Investigational Site
Escondido, California, 92025
Novo Nordisk Investigational Site
Evansville, Indiana, 47714
Novo Nordisk Investigational Site
Evergreen Park, Illinois, 60805
Novo Nordisk Investigational Site
Fairfax, Virginia, 22030
Novo Nordisk Investigational Site
Fort Smith, Arkansas, 72901
Novo Nordisk Investigational Site
Fresh Meadows, New York, 11365
Novo Nordisk Investigational Site
Glendale, Arizona, 85306
Novo Nordisk Investigational Site
Glendale, California, 91205
Novo Nordisk Investigational Site
Glendale, Wisconsin, 53209
Novo Nordisk Investigational Site
Greenville, North Carolina, 27834
Novo Nordisk Investigational Site
Gulfport, Mississippi, 39501
Novo Nordisk Investigational Site
Gurnee, Illinois, 60031
Novo Nordisk Investigational Site
Hagerstown, Maryland, 21740
Novo Nordisk Investigational Site
Hamlet, North Carolina, 28345
Novo Nordisk Investigational Site
Hampton, Virginia, 23667
Novo Nordisk Investigational Site
Hot Springs, Arkansas, 71901
Novo Nordisk Investigational Site
Houston, Texas, 77003
Novo Nordisk Investigational Site
Houston, Texas, 77004
Novo Nordisk Investigational Site
Houston, Texas, 77030
Novo Nordisk Investigational Site
Houston, Texas, 77099
Novo Nordisk Investigational Site
Indianapolis, Indiana, 46202
Novo Nordisk Investigational Site
Jackson, Mississippi, 39216
Novo Nordisk Investigational Site
Jacksonville, Florida, 32224
Novo Nordisk Investigational Site
Johnstown, Pennsylvania, 15905
Novo Nordisk Investigational Site
Kalamazoo, Michigan, 49007
Novo Nordisk Investigational Site
Kansas City, Kansas, 66160
Novo Nordisk Investigational Site
Kearney, Nebraska, 68848
Novo Nordisk Investigational Site
Killeen, Texas, 76543
Novo Nordisk Investigational Site
Knoxville, Tennessee, 37920
Novo Nordisk Investigational Site
Knoxville, Tennessee, 37923
Novo Nordisk Investigational Site
La Mesa, California, 91942
Novo Nordisk Investigational Site
Lafayatte, Louisiana, 70506
Novo Nordisk Investigational Site
Lakewood, California, 90712
Novo Nordisk Investigational Site
Lakewood, Colorado, 80214
Novo Nordisk Investigational Site
Lansing, Michigan, 48912
Novo Nordisk Investigational Site
Lewistown, Pennsylvania, 17044
Novo Nordisk Investigational Site
Lexington, Kentucky, 40513
Novo Nordisk Investigational Site
Little Rock, Arkansas, 72204
Novo Nordisk Investigational Site
Livingston, New Jersey, 07039
Novo Nordisk Investigational Site
Long Beach, California, 90822
Novo Nordisk Investigational Site
Los Alamitos, California, 90720
Novo Nordisk Investigational Site
Los Angeles, California, 90017
Novo Nordisk Investigational Site
Los Angeles, California, 90033
Novo Nordisk Investigational Site
Los Angeles, California, 90095
Novo Nordisk Investigational Site
Lubbock, Texas, 79430
Novo Nordisk Investigational Site
Lynwood, California, 90262
Novo Nordisk Investigational Site
Macon, Georgia, 31217
Novo Nordisk Investigational Site
Madison, Alabama, 35758
Novo Nordisk Investigational Site
Madisonville, Kentucky, 42431
Novo Nordisk Investigational Site
Marietta, Georgia, 30066
Novo Nordisk Investigational Site
Marshfield, Wisconsin, 54449
Novo Nordisk Investigational Site
Maywood, Illinois, 60153
Novo Nordisk Investigational Site
McAllen, Texas, 78503
Novo Nordisk Investigational Site
McGehee, Arkansas, 71654
Novo Nordisk Investigational Site
Meadville, Pennsylvania, 16335
Novo Nordisk Investigational Site
Mechanicsville, Virginia, 23116
Novo Nordisk Investigational Site
Medford, Oregon, 97504
Novo Nordisk Investigational Site
Merced, California, 95340
Novo Nordisk Investigational Site
Meridian, Idaho, 83642
Novo Nordisk Investigational Site
Miami, Florida, 33173
Novo Nordisk Investigational Site
Michigan City, Indiana, 46360
Novo Nordisk Investigational Site
Middlebury, Connecticut, 06762
Novo Nordisk Investigational Site
Milwaukee, Wisconsin, 53295
Novo Nordisk Investigational Site
Mineola, New York, 11501
Novo Nordisk Investigational Site
Minneapolis, Minnesota, 55404
Novo Nordisk Investigational Site
Mission Hills, California, 91345
Novo Nordisk Investigational Site
Mobile, Alabama, 36608
Novo Nordisk Investigational Site
Mobile, Alabama, 36617
Novo Nordisk Investigational Site
Monterey Park, California, 91745
Novo Nordisk Investigational Site
Montgomery, Alabama, 36106
Novo Nordisk Investigational Site
Mountain View, California, 94041
Novo Nordisk Investigational Site
Naples, Florida, 34119
Novo Nordisk Investigational Site
Nashville, Tennessee, 37203
Novo Nordisk Investigational Site
Nashville, Tennessee, 37205-1492
Novo Nordisk Investigational Site
Nashville, Tennessee, 37232
Novo Nordisk Investigational Site
Neenah, Wisconsin, 54956
Novo Nordisk Investigational Site
New Iberia, Louisiana, 70563
Novo Nordisk Investigational Site
New Orleans, Louisiana, 70112
Novo Nordisk Investigational Site
New Orleans, Louisiana, 70115
Novo Nordisk Investigational Site
New Orleans, Louisiana, 70121
Novo Nordisk Investigational Site
New York, New York, 10016
Novo Nordisk Investigational Site
New York, New York, 10021
Novo Nordisk Investigational Site
New York, New York, 10025
Novo Nordisk Investigational Site
Norfolk, Virginia, 23507
Novo Nordisk Investigational Site
North Charleston, South Carolina, 29405
Novo Nordisk Investigational Site
North Platte, Nebraska, 69101
Novo Nordisk Investigational Site
Orangeburg, South Carolina, 29115
Novo Nordisk Investigational Site
Orlando, Florida, 32804
Novo Nordisk Investigational Site
Orlando, Florida, 32806
Novo Nordisk Investigational Site
Oshkosh, Wisconsin, 54904
Novo Nordisk Investigational Site
Panama City, Florida, 32401
Novo Nordisk Investigational Site
Paragould, Arkansas, 72450
Novo Nordisk Investigational Site
Pasadena, California, 91106
Novo Nordisk Investigational Site
Pembroke Pines, Florida, 33024
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, 19104
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, 19140
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, 19144
Novo Nordisk Investigational Site
Phoenix, Arizona, 85012
Novo Nordisk Investigational Site
Pine Bluff, Arkansas, 71603
Novo Nordisk Investigational Site
Pittsburgh, Pennsylvania, 15224
Novo Nordisk Investigational Site
Pittsburgh, Pennsylvania, 15240
Novo Nordisk Investigational Site
Port Washington, New York, 11050
Novo Nordisk Investigational Site
Porterville, California, 93257
Novo Nordisk Investigational Site
Portsmouth, Virginia, 23704
Novo Nordisk Investigational Site
Providence, Rhode Island, 02904
Novo Nordisk Investigational Site
Provo, Utah, 84604
Novo Nordisk Investigational Site
Riverside, California, 92505
Novo Nordisk Investigational Site
Rochester, New York, 14621
Novo Nordisk Investigational Site
Rockville, Maryland, 20852
Novo Nordisk Investigational Site
Roseburg, Oregon, 97471
Novo Nordisk Investigational Site
Rosedale, New York, 11422
Novo Nordisk Investigational Site
Sacramento, California, 95825
Novo Nordisk Investigational Site
Saint Ann, Missouri, 63074
Novo Nordisk Investigational Site
Salem, Virginia, 24153
Novo Nordisk Investigational Site
San Antonio, Texas, 78207
Novo Nordisk Investigational Site
San Antonio, Texas, 78229
Novo Nordisk Investigational Site
Santee, South Carolina, 29142
Novo Nordisk Investigational Site
Seattle, Washington, 98133
Novo Nordisk Investigational Site
Shreveport, Louisiana, 71101
Novo Nordisk Investigational Site
Silver Spring, Maryland, 20906
Novo Nordisk Investigational Site
Sioux Falls, South Dakota, 57105
Novo Nordisk Investigational Site
Springfield, Massachusetts, 01107
Novo Nordisk Investigational Site
St Louis, Missouri, 63103
Novo Nordisk Investigational Site
St Louis, Missouri, 63108
Novo Nordisk Investigational Site
Stamford, Connecticut, 06902
Novo Nordisk Investigational Site
Sumter, South Carolina, 29150
Novo Nordisk Investigational Site
Tampa, Florida, 33603
Novo Nordisk Investigational Site
Tampa, Florida, 33614
Novo Nordisk Investigational Site
Tempe, Arizona, 85284
Novo Nordisk Investigational Site
The Bronx, New York, 10461
Novo Nordisk Investigational Site
The Bronx, New York, 10467
Novo Nordisk Investigational Site
Toledo, Ohio, 43606
Novo Nordisk Investigational Site
Topeka, Kansas, 66606
Novo Nordisk Investigational Site
Torrance, California, 90502
Novo Nordisk Investigational Site
Tucson, Arizona, 85719
Novo Nordisk Investigational Site
Tuscon, Arizona, 85723
Novo Nordisk Investigational Site
Tyler, Texas, 75701
Novo Nordisk Investigational Site
Vacaville, California, 95687
Novo Nordisk Investigational Site
Visalia, California, 93277
Novo Nordisk Investigational Site
Voorhees Township, New Jersey, 08043
Novo Nordisk Investigational Site
Walnut Creek, California, 94598
Novo Nordisk Investigational Site
Washington D.C., District of Columbia, 20002
Novo Nordisk Investigational Site
Weslaco, Texas, 78596
Novo Nordisk Investigational Site
Weston, Florida, 33331
Novo Nordisk Investigational Site
Whittier, California, 90602
Novo Nordisk Investigational Site
Whittier, California, 90603-2313
Novo Nordisk Investigational Site
Wichita, Kansas, 67214
Novo Nordisk Investigational Site
Wilmington, North Carolina, 28401
Novo Nordisk Investigational Site
Winston-Salem, North Carolina, 27101
Novo Nordisk Investigational Site
Xenia, Ohio, 45385
Novo Nordisk Investigational Site
Yonkers, New York, 10704
Novo Nordisk Investigational Site
Yuba City, California, 95991
Novo Nordisk Investigational Site
Zephyrhills, Florida, 33542
Germany27 sites
Novo Nordisk Investigational Site
Aschaffenburg, 63741
Novo Nordisk Investigational Site
Bad Mergentheim, 97980
Novo Nordisk Investigational Site
Bamberg, 96049
Novo Nordisk Investigational Site
Berlin, 10117
Novo Nordisk Investigational Site
Bernkastel-Kues, 54470
Novo Nordisk Investigational Site
Bottrop, 46242
Novo Nordisk Investigational Site
Dormagen, 41539
Novo Nordisk Investigational Site
Düsseldorf, 40210
Novo Nordisk Investigational Site
Elsenfeld, 63820
Novo Nordisk Investigational Site
Fürstenzell, 94081
Novo Nordisk Investigational Site
Gütersloh, 33332
Novo Nordisk Investigational Site
Hamburg, 22297
Novo Nordisk Investigational Site
Hamburg, 22767
Novo Nordisk Investigational Site
Hanover, 30625
Novo Nordisk Investigational Site
Heilbronn, 74076
Novo Nordisk Investigational Site
Kiel, 24106
Novo Nordisk Investigational Site
Krefeld, 47798
Novo Nordisk Investigational Site
Limburg an der Lahn, 65549
Novo Nordisk Investigational Site
Lüdenscheid, 58515
Novo Nordisk Investigational Site
Mettmann, 40822
Novo Nordisk Investigational Site
Minden, 32425
Novo Nordisk Investigational Site
Nettetal, 41334
Novo Nordisk Investigational Site
Passau, 94032
Novo Nordisk Investigational Site
Schweinfurt, 97421
Novo Nordisk Investigational Site
Straubing, 94315
Novo Nordisk Investigational Site
Würzburg, 97072
Novo Nordisk Investigational Site
Würzburg, 97080
France17 sites
Novo Nordisk Investigational Site
Béziers, 34500
Novo Nordisk Investigational Site
Bordeaux, 33000
Novo Nordisk Investigational Site
Bordeaux, 33076
Novo Nordisk Investigational Site
Cherbourt-Octeville, 50102
Novo Nordisk Investigational Site
Clermont-Ferrand, 63000
Novo Nordisk Investigational Site
Dunkirk, 59385
Novo Nordisk Investigational Site
Lyon, 69437
Novo Nordisk Investigational Site
Montpellier, 34295
Novo Nordisk Investigational Site
Muret, 31603
Novo Nordisk Investigational Site
Nantes, 44093
Novo Nordisk Investigational Site
Paris, 75013
Novo Nordisk Investigational Site
Paris, 75015
Novo Nordisk Investigational Site
Paris, 75016
Novo Nordisk Investigational Site
Paris, 75018
Novo Nordisk Investigational Site
Poissy, 78300
Novo Nordisk Investigational Site
Trappes, 78190
Novo Nordisk Investigational Site
Vichy, 3209
Poland14 sites
Novo Nordisk Investigational Site
Krakow, 31-908
Novo Nordisk Investigational Site
Kraśnik, 23-210
Novo Nordisk Investigational Site
Kwidzyn, 82-500
Novo Nordisk Investigational Site
Myślenice, 32-400
Novo Nordisk Investigational Site
Ostrów Mazowiecka, 07-300
Novo Nordisk Investigational Site
Poznann, 60-355
Novo Nordisk Investigational Site
Puławy, 24-100
Novo Nordisk Investigational Site
Radom, 26-617
Novo Nordisk Investigational Site
Sieradz, 98-200
Novo Nordisk Investigational Site
Słupca, 63-400
Novo Nordisk Investigational Site
Sochaczew, 96-500
Novo Nordisk Investigational Site
Ul Mlynska 5, 33-300
Novo Nordisk Investigational Site
Wejherowo, 84-200
Novo Nordisk Investigational Site
Wroclaw, 51-124
United Kingdom14 sites
Novo Nordisk Investigational Site
Aberdeen, AB25 2ZN
Novo Nordisk Investigational Site
Birmingham, B9 5ST
Novo Nordisk Investigational Site
Cambridge, CB2 2QQ
Novo Nordisk Investigational Site
Coventry, CV2 2DX
Novo Nordisk Investigational Site
Glasgow, G11 6NT
Novo Nordisk Investigational Site
Leicester, LE5 4PW
Novo Nordisk Investigational Site
Liverpool, L69 3GA
Novo Nordisk Investigational Site
London, NW3 2QG
Novo Nordisk Investigational Site
Londonderry, BT47 6SB
Novo Nordisk Investigational Site
Manchester, M13 9WL
Novo Nordisk Investigational Site
Rhyl, LL18 5UJ
Novo Nordisk Investigational Site
Sheffield, S5 7AU
Novo Nordisk Investigational Site
Swansea, SA6 6NL
Novo Nordisk Investigational Site
Wolverhampton, WV10 0QP
Brazil11 sites
Novo Nordisk Investigational Site
Curitiba, 81050-090
Novo Nordisk Investigational Site
Fortaleza, 60336-550
Novo Nordisk Investigational Site
Fortaleza, 60430-370
Novo Nordisk Investigational Site
Jaboatao de Guararapes, 54400-170
Novo Nordisk Investigational Site
Porto Alegre, 90035-903
Novo Nordisk Investigational Site
Porto Alegre, 90420090
Novo Nordisk Investigational Site
Porto Alegre, 90610000
Novo Nordisk Investigational Site
Rio de Janeiro, Rio de Janeiro, 22260-020
Novo Nordisk Investigational Site
São José Rio Preto, 15090-000
Novo Nordisk Investigational Site
São Paulo, 04039001
Novo Nordisk Investigational Site
Sorocaba, 18030-083
Canada11 sites
Novo Nordisk Investigational Site
Edmonton, Alberta, T6G 2B7
Novo Nordisk Investigational Site
Greenfield Park, J4V 2H1
Novo Nordisk Investigational Site
Halifax, Nova Scotia, B3H 1V7
Novo Nordisk Investigational Site
London, N6A 5A5
Novo Nordisk Investigational Site
Montreal, Quebec, HIT 2M4
Novo Nordisk Investigational Site
Peterborough, K9J 7C6
Novo Nordisk Investigational Site
Regina, S4P 0W5
Novo Nordisk Investigational Site
Saskatoon, S7M 2Z1
Novo Nordisk Investigational Site
Scarborough, M1H 3G4
Novo Nordisk Investigational Site
Thunder Bay, P7B 6V4
Novo Nordisk Investigational Site
Toronto, Ontario, M5B 1W8
Argentina10 sites
Novo Nordisk Investigational Site
Buenos Aires, B1636DSU
Novo Nordisk Investigational Site
Buenos Aires, C1181ACH
Novo Nordisk Investigational Site
Capital Federal, C1425BPM
Novo Nordisk Investigational Site
Capital Federal, C1431FWO
Novo Nordisk Investigational Site
Córdoba, X5002HWE
Novo Nordisk Investigational Site
Morón, B1708DPO
Novo Nordisk Investigational Site
Pergamino, B2700CPM
Novo Nordisk Investigational Site
San Miguel de Tucumán, 4000
Novo Nordisk Investigational Site
Sarandí, B1872EEA
Novo Nordisk Investigational Site
Temperley, 1834
Portugal10 sites
Novo Nordisk Investigational Site
Abrantes, 2200-233
Novo Nordisk Investigational Site
Amadora, 2700-473
Novo Nordisk Investigational Site
Braga, 4710-391
Novo Nordisk Investigational Site
Corroios, 2855-227
Novo Nordisk Investigational Site
Entroncamento, 2330-108
Novo Nordisk Investigational Site
Evora, 7000-711
Novo Nordisk Investigational Site
Setúbal, 2900-655
Novo Nordisk Investigational Site
Torres Vedras, 2560-272
Novo Nordisk Investigational Site
Villa Franca de Xira, 2600-076
Novo Nordisk Investigational Site
Villa Nova de Gaia, 4430-196
Russia8 sites
Novo Nordisk Investigational Site
Moscow, 123182
Novo Nordisk Investigational Site
Moscow, 125284
Novo Nordisk Investigational Site
Petrozavodsk, 185019
Novo Nordisk Investigational Site
Saint Petersburg, 191015
Novo Nordisk Investigational Site
Saint Petersburg, 191104
Novo Nordisk Investigational Site
Saint Petersburg, 195067
Novo Nordisk Investigational Site
Saint Petersburg, 195257
Novo Nordisk Investigational Site
Saint Petersburg, 197022
Spain8 sites
Novo Nordisk Investigational Site
Barcelona, 8029
Novo Nordisk Investigational Site
Burgos, 9006
Novo Nordisk Investigational Site
Córdoba, 14005
Novo Nordisk Investigational Site
Granollers, 8401
Novo Nordisk Investigational Site
Madrid, 28006
Novo Nordisk Investigational Site
Santander, 39001
Novo Nordisk Investigational Site
Seville, 41013
Novo Nordisk Investigational Site
Valencia, 96007
Denmark7 sites
Novo Nordisk Investigational Site
Aalborg, 9100
Novo Nordisk Investigational Site
Arhus N, 8200
Novo Nordisk Investigational Site
Copenhagen, 2100
Novo Nordisk Investigational Site
Herlev, 2730
Novo Nordisk Investigational Site
Hilleroed, 3400
Novo Nordisk Investigational Site
Holbæk, 4300
Novo Nordisk Investigational Site
Odense, 5000
Israel7 sites
Novo Nordisk Investigational Site
Ashkelon, 78278
Novo Nordisk Investigational Site
Hadera, 38100
Novo Nordisk Investigational Site
Haifa, 34362
Novo Nordisk Investigational Site
Jerusalem
Novo Nordisk Investigational Site
Petah Tikva, 49100
Novo Nordisk Investigational Site
Rehovot
Novo Nordisk Investigational Site
Tzriffin, 70300
Italy6 sites
Novo Nordisk Investigational Site
Bologna, 40138
Novo Nordisk Investigational Site
Brescia, 23125
Novo Nordisk Investigational Site
Genova, 16132
Novo Nordisk Investigational Site
Milan, 20142
Novo Nordisk Investigational Site
Modena, 41100
Novo Nordisk Investigational Site
Pavia, 27100
Hungary5 sites
Novo Nordisk Investigational Site
Budapest, 1083
Novo Nordisk Investigational Site
Budapest, 1097
Novo Nordisk Investigational Site
Eger, 3300
Novo Nordisk Investigational Site
Kecskemét, 6001
Novo Nordisk Investigational Site
Sopron, 9400
China4 sites
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, 100050
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, 100853
Novo Nordisk Investigational Site
Nanjing, Jiangsu, 210009
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, 200001
Turkey (Türkiye)4 sites
Novo Nordisk Investigational Site
Ankara, 06500
Novo Nordisk Investigational Site
Istanbul, 34360
Novo Nordisk Investigational Site
Istanbul, 34390
Novo Nordisk Investigational Site
Istanbul, 34668
India3 sites
Novo Nordisk Investigational Site
Hyderabad, Andhra Pradesh, 500082
Novo Nordisk Investigational Site
Hyderabad, 500034
Novo Nordisk Investigational Site
Pune, 411011
Sweden3 sites
Novo Nordisk Investigational Site
Stockholm, 182 88
Novo Nordisk Investigational Site
Uppsala, 751 85
Novo Nordisk Investigational Site
Värnamo, 331 85
South Africa2 sites
Novo Nordisk Investigational Site
Johannesburg, Gauteng, 2013
Novo Nordisk Investigational Site
Obervatory, 7925
About this study
Official title: Efficacy and Safety of Somatropin in Adult Patients on Chronic Haemodialysis
This trial is conducted in Africa, Asia, Europe, North and South America and Oceania.
The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health related quality of life in adult patients on chronic haemodialysis.
Read the detailed description
The decision to discontinue the trial is not due to safety concerns. The discontinuation is based on an analysis of the significant delay in recruitment of patients which is expected to have a negative impact on the outcome of the trial.
- Conditions
- Chronic Kidney Disease, End-Stage Renal Disease
- Being tested
- somatropin, placebo
- Medical subject headings
- Renal Insufficiency, Chronic, Kidney Failure, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
somatropinDrug
20 mcg/kg/day, injected s.c. (under the skin)
placeboDrug
Placebo injected s.c (under the skin)
| Study group | Role | What they receive |
|---|---|---|
| Somatropin | Experimental | Somatropin once daily from week 0 to end of trial Receives: Drug: somatropin |
| Placebo | Placebo comparator | Placebo once daily to end of trial Receives: Drug: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality - Time to All-cause Death
Time to all-cause death. Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants dead estimated using Kaplan-Meier. Summary data illustrates mortality until 52 weeks, because very few subjects had trial time longer than 52 weeks. Due to early trial termination, median trial time was 17.4 weeks.
Measured: week 0, trial termination
Secondary outcomes (4)
Morbidity - Time From Randomisation to Next Cardiovascular Event (Defined as Composite of All-cause Mortality, Non-fatal Myocardial Infarction, Stroke, Cardiac Insufficiency and Other Thrombo-embolic Event)
Morbidity - time from week 0 to next cardiovascular event (composite of all-cause mortality and cardiovascular events defined as adjudicated medical event of special interest and categorised as myocardial infarctions, cardiac insufficiencies, strokes or other thrombo-embolic events). Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants with events estimated using Kaplan-Meier. Summary data illustrates morbidity until 52 weeks, because very few subjects had trial time longer than 52 weeks.
Measured: week 0, trial termination
Morbidity - Number of Hospitalisations, in Addition to Normal Dialysis Procedures
The number of times that the patient was hospitalised in addition to hospitalisation for normal dialysis procedures measured from week 0 (randomisation) to the time the trial was terminated.
Measured: week 0, trial termination
Mortality - Two-year Mortality Rate
Measured: week 0, trial termination
Health Related Quality of Life Assessments
Summary from activity of daily living from the Rotterdam Symptom Checklist (RSCL) measuring activity from 1 (active) to 5 (inactive). The Edmonton Symptom Assessment System (ESAS), subjects assess their health in the last 24 hours on a scale from 1 (good health) to 3 (feeling poorly). The EQ-5D is a measure of subjects' health outcome from 0 (death) to 1 (full health). SF-36 (Short Form (36)) covering mental and physicial health is provided in a scale from 0-100 with higher scores indicating greater satisfaction.
Measured: week 0, trial termination
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jul 2007 (estimated)
- Study startJul 2007
- Primary completionDec 2008
- Study completionDec 2008
Why it stopped: See termination reason in detailed description
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Chronic Kidney DiseaseStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 712 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Global Clinical Registry (GCR, 1452), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00503698
- Sponsor's protocol ID
- NN1630-1453
- Other IDs
- 2006-004702-56
- Acronym
- OPPORTUNITY
- Status last verified
- Jan 2017
- First submitted
- 18 Jul 2007
- Last updated
- 7 Mar 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M, Feldt-Rasmussen B, Lange M, Mitch WE, Wanner C, Wiedemann J, Ikizler TA. OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol. 2008 Nov;3(6):1741-51. doi: 10.2215/CJN.02760608.
PubMed 18945992Raff AC, Meyer TW, Hostetter TH. New insights into uremic toxicity. Curr Opin Nephrol Hypertens. 2008 Nov;17(6):560-5. doi: 10.1097/MNH.0b013e32830f45b6.
PubMed 18941347
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Somatropin in Adult Patients on Chronic Haemodialysis
- ClinicalTrials.gov ID
- NCT00503698
- Acronym / sponsor ID
- OPPORTUNITY / NN1630-1453
- Conditions
- Chronic Kidney Disease, End-Stage Renal Disease
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: See termination reason in detailed description
- Enrolment
- 712 participants (actual)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- Jul 2007
- Primary completion
- Dec 2008 (actual)
- Study completion
- Dec 2008 (actual)
- First posted
- 19 Jul 2007 (estimated)
- Results
- Posted 13 Jul 2010
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial is conducted in Africa, Asia, Europe, North and South America and Oceania.
The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health related quality of life in adult patients on chronic haemodialysis.
Detailed description
The decision to discontinue the trial is not due to safety concerns. The discontinuation is based on an analysis of the significant delay in recruitment of patients which is expected to have a negative impact on the outcome of the trial.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Somatropin | Experimental | Drug: somatropinSomatropin once daily from week 0 to end of trial |
| Placebo | Placebo comparator | Drug: placeboPlacebo once daily to end of trial |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Serum albumin as specified in protocol
- Malnourished (based on serum albumin value below 40 g/L, assessed centrally)
- Stable (for 3 months or more) and adequate haemodialysis treatment three months prior to enrolment as defined by Kt/V of more than 1.2
Key exclusion criteria (8 listed)
- Active malignant disease
- Critical illness requiring treatment in an intensive care unit (ICU)
- Uncontrolled treated/untreated hypertension
- Patients on chronic (more than 3 months) treatment with steroids in doses of more than 10 mg/day prednisolone (or equivalent)
- Patients treated with immunosuppressive agents
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| somatropin20 mcg/kg/day, injected s.c. (under the skin) | Drug | Somatropin |
| placeboPlacebo injected s.c (under the skin) | Drug | Placebo |
Primary outcome
Mortality - Time to All-cause Death
Time frame: week 0, trial termination
Time to all-cause death. Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants dead estimated using Kaplan-Meier. Summary data illustrates mortality until 52 weeks, because very few subjects had trial time longer than 52 weeks. Due to early trial termination, median trial time was 17.4 weeks.
4 secondary outcomes
Morbidity - Time From Randomisation to Next Cardiovascular Event (Defined as Composite of All-cause Mortality, Non-fatal Myocardial Infarction, Stroke, Cardiac Insufficiency and Other Thrombo-embolic Event)
Time frame: week 0, trial termination
Morbidity - Number of Hospitalisations, in Addition to Normal Dialysis Procedures
Time frame: week 0, trial termination
Mortality - Two-year Mortality Rate
Time frame: week 0, trial termination
Health Related Quality of Life Assessments
Time frame: week 0, trial termination
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 18945992Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M, Feldt-Rasmussen B, Lange M, Mitch WE, Wanner C, Wiedemann J, Ikizler TA. OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol. 2008 Nov;3(6):1741-51. doi: 10.2215/CJN.02760608.
- Results publication: PubMed 18941347Raff AC, Meyer TW, Hostetter TH. New insights into uremic toxicity. Curr Opin Nephrol Hypertens. 2008 Nov;17(6):560-5. doi: 10.1097/MNH.0b013e32830f45b6.
- Clinical Trials at Novo NordiskLink provided by the sponsor.
Related trials for Chronic Kidney Disease
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Global Clinical Registry (GCR, 1452) study director
Novo Nordisk A/S
381 sites in 21 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing somatropin in people with Chronic Kidney Disease and End-Stage Renal Disease, run by Novo Nordisk A/S at 381 sites in 21 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 7 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 381 sites in United States, Germany, France, Poland, United Kingdom and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 Jul 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality - Time to All-cause Death (time frame: week 0, trial termination). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00503698, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2017.